International Working Group on Neurotransmitter Related Disorders

Topical Oxygen Therapy Awarded Positive Treatment Recommendation by the International Working Group on the Diabetic Foot in their 2023 Diabetic Foot Ulcer Guidelines

Retrieved on: 
Lundi, mai 15, 2023
Real, DFU, E pluribus unum, Multicenter Automatic Defibrillator Implantation Trial, American Diabetes Association, International Working Group on Neurotransmitter Related Disorders, Olympic Games, Diabetic foot ulcer, Efficacy, RCT, Humidity, International Symposium on Endovascular Therapy, Ulcer, Randomness, Patient, ISDF, Randomized controlled trial, ADA, Diabetic foot, News, Diabetes, Treatment, Pharmaceutical industry, Dietary supplement, Medical device

OCEANSIDE, Calif., May 15, 2023 /PRNewswire/ -- AOTI Inc, the global leader in multi-modality topical wound oxygen, announced exciting news from the 9th International Symposium on the Diabetic Foot (ISDF).

Key Points: 
  • OCEANSIDE, Calif., May 15, 2023 /PRNewswire/ -- AOTI Inc, the global leader in multi-modality topical wound oxygen, announced exciting news from the 9th International Symposium on the Diabetic Foot (ISDF).
  • The International Working Group on the Diabetic Foot (IWGDF) unveiled its 2023 Guidelines on Interventions to Enhance Healing of Foot Ulcers in People with Diabetes:
    https://iwgdfguidelines.org/guidelines-2023/ .
  • In these newly released guidelines, topical oxygen therapy was awarded a positive adjunctive treatment recommendation, consistent with the "A" grade recommendation previously awarded by the American Diabetes Association (ADA) in their Standards of Care in Diabetes 2023: https://diabetesjournals.org/care/issue/46/Supplement_1 .
  • 2 Reduced Hospitalizations and Amputations in Patients with Diabetic Foot Ulcers Treated with Cyclical Pressurized Topical Wound Oxygen Therapy: Real-World Outcomes; Jessica Izhakoff Yellin, et al; Advances in Wound Care 2022; http://doi.org/10.1089/wound.2021.0118

Ubie signs a broad collaboration agreement with Takeda Pharmaceuticals to promote digital transformation

Retrieved on: 
Jeudi, avril 27, 2023
Learning, Face, International Working Group on Neurotransmitter Related Disorders, Takeda, HAWK, E pluribus unum, Edema, Hereditary angioedema, Angioedema, Asphyxia, Asthma, HAE, Genetic disorder, Patient, Physician, Risk, Abdomen, Diagnosis, Rare, Health, Audi Q5, Disease, Pharmaceutical industry, Nursing

NEW YORK, April 27, 2023 /PRNewswire/ -- Ubie Inc. has signed a comprehensive collaboration agreement with Takeda Pharmaceutical Co., Ltd. to promote digital transformation, which aims to guide people to appropriate medical care for rare diseases and gastrointestinal diseases.

Key Points: 
  • NEW YORK, April 27, 2023 /PRNewswire/ -- Ubie Inc. has signed a comprehensive collaboration agreement with Takeda Pharmaceutical Co., Ltd. to promote digital transformation, which aims to guide people to appropriate medical care for rare diseases and gastrointestinal diseases.
  • Since April 2021, Ubie and Takeda Pharmaceutical Co., Ltd. have been promoting digital transformation for the early detection of diseases and guidance for appropriate medical examinations using Ubie Symptom Checker, a service for general public with disease concerns, and Ubie Patient Intake Form, a service for medical institutions.
  • (*2,3,4) If it lodges in the throat, it can block the airway, causing difficulty breathing and the elevating risk of suffocation.
  • Ubie, in collaboration with Takeda, will contribute to the health of as many patients as possible by supporting patient journeys through the active use of technology.

Modulim Announces Intent to Drive Value-Based Care in Nephrology Market With Custom Limb Preservation Solution

Retrieved on: 
Mercredi, juillet 6, 2022
Cloud, Health, Death, Diabetic foot, Centers for Medicare & Medicaid Services, LAMP, ESRD, Patient, Dialysis, CMS, Keck School of Medicine of USC, Center, Population, Cancer, International Working Group on Neurotransmitter Related Disorders, Chronic kidney disease, Amputation, BMC, Moyamoya disease, Ulcer, Prevalence, Diabetes, Risk, Statistics, Technology, Standard of care, CA, SALSA, CKD, Risk factor, Kidney disease, KCC, Medicare, Pharmaceutical industry, Medical imaging

The new KCC value-based care program incentivizes proactive care coordination to reduce preventable hospitalizations, improve patient outcomes, and reduce the total cost of care.

Key Points: 
  • The new KCC value-based care program incentivizes proactive care coordination to reduce preventable hospitalizations, improve patient outcomes, and reduce the total cost of care.
  • Modulim has developed the LAMP solution that integrates Clarifi Imaging System and Modulim Cloud to deliver actionable clinical insights for the management of high-risk patients.
  • "The new KCC value-based care programs incentivize proactive care coordination to reduce preventable hospitalizations and improve outcomes.
  • Modulim delivers transformative imaging and data solutions that empower clinicians to better diagnose, treat, and manage lower limb complications.

Molecular International Prognostic Scoring System Developed for Myelodysplastic Syndromes

Retrieved on: 
Dimanche, juin 12, 2022
International Working Group on Neurotransmitter Related Disorders, Memorial Sloan Kettering Cancer Center, Research, Catalog, Marie Cassidy, International Prognostic Scoring System, Analysis, IPSS, AML, Gene, MDS, Cytogenetics, Myelodysplastic syndrome, GLOBE, Patient, Risk, Adoption, Diagnosis, The New England Journal of Medicine, IWG, Leukemia, Death, Prognosis, Medical device, Pharmaceutical industry

YARDVILLE, N.J., June 12, 2022 (GLOBE NEWSWIRE) -- Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk stratification upon diagnosis to better inform the way treatment plans are built for patients with Myelodysplastic Syndromes.

Key Points: 
  • YARDVILLE, N.J., June 12, 2022 (GLOBE NEWSWIRE) -- Today, the MDS Foundation announced the development of a new prognostic scoring system, the IPSS-Molecular, that will significantly improve risk stratification upon diagnosis to better inform the way treatment plans are built for patients with Myelodysplastic Syndromes.
  • For more than two decades, MDS patient risk stratification at diagnosis was based on diagnostic blood counts, morphology, and cytogenetics through the International Prognostic Scoring System.
  • The creation of an effective set of prognostic guidelines was especially important for MDS because current clinical courses are very heterogeneous.
  • The results of this investigation, led by Drs Elsa Bernard, Elli Papaemmanuil and IWG colleagues, 'Molecular International Prognostic Scoring System for MDS (IPSS-M)', have just been published in the June 12, 2022 issue of the New England Journal of Medicine Evidence.

Zai Lab Partner argenx Announces Positive Phase 3 Data from ADVANCE Trial of VYVGART® (efgartigimod alfa-fcab) in Adults with Primary Immune Thrombocytopenia

Retrieved on: 
Jeudi, mai 5, 2022
Intracranial hemorrhage, Drug development, Fortnight, Immunoglobulin G, Splenectomy, Safety, GMG, Depression, Bleeding, Prevalence, Anxiety, Administration, SEC, Risk, Forward-looking statement, Euronext, Acetylcholine receptor, NASDAQ, Neonatal Fc receptor, Patient, Bruise, Incidence, Rituximab, ITP, Mental health, Research, SAN, Platelet, L, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, International Working Group on Neurotransmitter Related Disorders, Time, Immune thrombocytopenic purpura, HKEX, Degenerative disease, COVID-19, Fear, GLOBE, Steroid, Immunoglobulin therapy, Coronavirus, Diagnosis, Anemia, History, Adult, Health, IWG, Infection, Autoantibody, Medical imaging, Fine chemical, Pharmaceutical industry, Vaccine, Security (finance)

SHANGHAI, China and SAN FRANCISCO and CAMBRIDGE, Mass., May 05, 2022 (GLOBE NEWSWIRE) -- Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the company’s partner argenx (Euronext & Nasdaq: ARGX) reported positive data from the Phase 3 ADVANCE trial of VYVGART® (efgartigimod alfa-fcab).

Key Points: 
  • In adults with primary ITP, ADVANCE met its primary endpoint demonstrating that a higher proportion of chronic ITP patients receiving VYVGART achieved a sustained platelet count response compared to placebo.
  • ADVANCE is the first Phase 3 clinical trial of a neonatal Fc receptor (FcRn) blocker in ITP.
  • Additional secondary endpoint data from the ADVANCE trial are consistent with primary and secondary platelet-derived endpoints and provide additional context on metrics that often drive treatment decisions.
  • The Phase 3 ADVANCE trial was a randomized, double-blind, placebo-controlled, multicenter, global trial evaluating the efficacy and safety of VYVGART in adult patients with chronic or persistent primary ITP.

Biosight Announces Initiation of Phase 2 Clinical Trial of Aspacytarabine for MDS and AML

Retrieved on: 
Vendredi, novembre 12, 2021
Society, Population, Agreement, AML, Bone marrow, CR, Securities Exchange Act of 1934, THE, Interim, Therapy, Plan, Securities Act of 1933, Communication, Risk, Safety, VP, Asparagine, Person, Acute myeloid leukemia, Endpoint security, Forward-looking statement, Memorial Sloan Kettering Cancer Center, Academic health science centre, GLOBE, Fast track (FDA), Cytarabine, Patient, FDA, Documentation, Adult, Lymphatic system, Disorder, U.S. Securities and Exchange Commission, Tripura Merger Agreement, Goal, LLC, Corporate action, IWG, Metabolism, SEC, Pharmacokinetics, ORR, International Working Group on Neurotransmitter Related Disorders, University, Form, Adoption, Form 8-K, MRD, EMA, ASH, MDS, Attention, MD Anderson Cancer Center, Annual report, GFM, Toxicity, SPECIAL, Pharmaceutical industry, Cryptocurrency, Bank

AIRPORT CITY, Israel, Nov. 12, 2021 (GLOBE NEWSWIRE) -- Biosight Ltd., a pharmaceutical development company developing innovative therapeutics for hematological malignancies and disorders, today announced the initiation of a Phase 2 trial to evaluate aspacytarabine (BST-236), Biosight’s proprietary antimetabolite, as a second line treatment for patients with relapsed or refractory myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The multi-center study will be conducted across 18 leading U.S. and Israeli sites including Memorial Sloan Kettering Cancer Center and The University of Texas MD Anderson Cancer Center.

Key Points: 
  • The initiation of this multi-center, U.S. based, Phase 2 study is an important step forward in the development of aspacytarabine, seeking to address unmet needs in the treatment of patients with relapsed or refractory AML and MDS.
  • Patients with relapsed or refractory AML and MDS have limited treatment options and poor prognoses, with many patients unable to tolerate intensive chemotherapy.
  • Biosight is a private Phase 2 clinical stage biotech company developing innovative therapeutics for hematological malignancies and disorders.
  • Aspacytarabine is currently being investigated as a single agent in a Phase 2b clinical trial, which recently completed enrollment, for the first-line treatment of AML.